Kevin R Nash

List of Publications by Year
in descending order

55 papers	2,907 citations	172457 29 h-index	175258 52 g-index
56 all docs	56 docs citations	56 times ranked	4135 citing authors

#	Article	IF	Citations
1	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. GeroScience, 2022, 44, 173-194.	4.6	6
2	CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. , 2022, 231, 107989.		53
3	Recovery of Angelman syndrome rat deficits with UBE3A protein supplementation. Molecular and Cellular Neurosciences, 2022, 120, 103724.	2.2	1
4	Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A. Neurotherapeutics, 2022, 19, 1329-1339.	4.4	3
5	Reelin central fragment supplementation improves cognitive deficits in a mouse model of Fragile X Syndrome. Experimental Neurology, 2022, 357, 114170.	4.1	1
6	Identification of <scp>UBE3A</scp> Protein in <scp>CSF</scp> and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity. Autism Research, 2021, 14, 645-655.	3.8	5
7	Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology. Journal of Clinical Investigation, 2021, 131, .	8.2	20
8	Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome. ENeuro, 2021, 8, ENEURO.0345-20.2020.	1.9	20
9	Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors. Frontiers in Neurology, 2021, 12, 685802.	2.4	13
10	STK35 Gene Therapy Attenuates Endothelial Dysfunction and Improves Cardiac Function in Diabetes. Frontiers in Cardiovascular Medicine, 2021, 8, 798091.	2.4	2
11	Overexpression of human wtTDP-43 causes impairment in hippocampal plasticity and behavioral deficits in CAMKII-tTa transgenic mouse model. Molecular and Cellular Neurosciences, 2020, 102, 103418.	2.2	7
12	TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. Journal of Neuroinflammation, 2020, 17, 283.	7.2	32
13	T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an Î±-synuclein rat model of Parkinsonâ€™s disease. Journal of Neuroinflammation, 2020, 17, 242.	7.2	54
14	Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice. Journal of Neuroinflammation, 2020, 17, 157.	7.2	33
15	Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion. Autism Research, 2020, 13, 397-409.	3.8	28
16	CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy. Frontiers in Immunology, 2020, 11, 997.	4.8	54
17	Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response. Alzheimer's Research and Therapy, 2019, 11, 58.	6.2	29
18	Neuroinflammation and fractalkine signaling in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2019, 16, 30.	7.2	93

#	Article	IF	Citations
19	Automatic stereology of mean nuclear size of neurons using an active contour framework. Journal of Chemical Neuroanatomy, 2019, 96, 110-115.	2.1	3
20	CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model. Journal of NeuroImmune Pharmacology, 2019, 14, 312-325.	4.1	25
21	Astaxanthin is neuroprotective in an aged mouse model of Parkinsonâ€™s disease. Oncotarget, 2018, 9, 10388-10401.	1.8	45
22	Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. GeroScience, 2017, 39, 19-32.	4.6	138
23	Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinsonâ€™s Disease. Brain Sciences, 2016, 6, 41.	2.3	18
24	Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. Journal of Immunological Methods, 2016, 432, 51-56.	1.4	6
25	Small-Scale Recombinant Adeno-Associated Virus Purification. Methods in Molecular Biology, 2016, 1382, 95-106.	0.9	16
26	Convection Enhanced Delivery of Recombinant Adeno-associated Virus into the Mouse Brain. Methods in Molecular Biology, 2016, 1382, 285-295.	0.9	6
27	P3-048: Arginine metabolism and higher-order polyamines impact tau aggregation, microtubule assembly, and autophagy in models of tauopathies. , 2015, 11, P636-P637.		3
28	P3-007: Characterization of full length and c-terminal truncated tau pathological progression with age in wild type mice. , 2015, 11, P621-P622.		0
29	Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. Journal of Neuroscience, 2015, 35, 14842-14860.	3.6	37
30	Fractalkine Over Expression Suppresses Î±-Synuclein-mediated Neurodegeneration. Molecular Therapy, 2015, 23, 17-23.	8.2	68
31	Anti-Human Î±-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-Î±-Synuclein Rat Model of Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0116841.	2.5	68
32	Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Research and Therapy, 2014, 6, 12.	6.2	105
33	Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of Neuroinflammation, 2013, 10, 86.	7.2	78
34	Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of Aging, 2013, 34, 1610-1620.	3.1	105
35	Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of Aging, 2013, 34, 1540-1548.	3.1	89
36	Intracranial Injection of AAV Expressing NEP but Not IDE Reduces Amyloid Pathology in APP+PS1 Transgenic Mice. PLoS ONE, 2013, 8, e59626.	2.5	36

#	Article	IF	Citations
37	The Soluble Isoform of CX3CL1 Is Necessary for Neuroprotection in a Mouse Model of Parkinson's Disease. Journal of Neuroscience, 2012, 32, 14592-14601.	3.6	105
38	Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load. Journal of NeuroImmune Pharmacology, 2012, 7, 202-214.	4.1	9
39	Adeno-Associated Virus-Mediated Rescue of the Cognitive Defects in a Mouse Model for Angelman Syndrome. PLoS ONE, 2011, 6, e27221.	2.5	92
40	Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of Neuroscience Methods, 2010, 194, 144-153.	2.5	61
41	Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain. Journal of Neurochemistry, 2010, 114, 1158-1167.	3.9	43
42	Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. Journal of Neuroscience, 2010, 30, 9651-9658.	3.6	116
43	In Vivo RNAi-Mediated Î±-Synuclein Silencing Induces Nigrostriatal Degeneration. Molecular Therapy, 2010, 18, 1450-1457.	8.2	173
44	The Effect of DNA-Dependent Protein Kinase on Adeno-Associated Virus Replication. PLoS ONE, 2010, 5, e15073.	2.5	23
45	Identification of Cellular Proteins That Interact with the Adeno-Associated Virus Rep Protein. Journal of Virology, 2009, 83, 454-469.	3.4	56
46	Heparin binding induces conformational changes in Adeno-associated virus serotype 2. Journal of Structural Biology, 2009, 165, 146-156.	2.8	98
47	Complete In Vitro Reconstitution of Adeno-Associated Virus DNA Replication Requires the Minichromosome Maintenance Complex Proteins. Journal of Virology, 2008, 82, 1458-1464.	3.4	52
48	Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces AÎ² Deposits in APP + PS1 Transgenic Mice. Molecular Therapy, 2008, 16, 1580-1586.	8.2	64
49	Purification of Host Cell Enzymes Involved in Adeno-Associated Virus DNA Replication. Journal of Virology, 2007, 81, 5777-5787.	3.4	32
50	Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molecular Therapy, 2006, 13, 463-483.	8.2	118
51	Recombinant Adeno-Associated Viral Vectors in the Nervous System. Human Gene Therapy, 2005, 16, 781-791.	2.7	97
52	Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular Therapy, 2005, 12, 618-633.	8.2	251
53	Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System. Molecular Therapy, 2005, 12, 1217-1225.	8.2	116
54	Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. Archives of Biochemistry and Biophysics, 2004, 424, 154-162.	3.0	54

#	Article	IF	Citations
55	Recombinant Human and Mouse Purple Acid Phosphatases: Expression and Characterization. Archives of Biochemistry and Biophysics, 1997, 345, 230-236.	3.0	47